<SEC-DOCUMENT>0001326732-25-000086.txt : 20251105
<SEC-HEADER>0001326732-25-000086.hdr.sgml : 20251105
<ACCEPTANCE-DATETIME>20251105160213
ACCESSION NUMBER:		0001326732-25-000086
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251105
DATE AS OF CHANGE:		20251105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xencor Inc
		CENTRAL INDEX KEY:			0001326732
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				201622502
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36182
		FILM NUMBER:		251453760

	BUSINESS ADDRESS:	
		STREET 1:		465 N. HALSTEAD ST.
		STREET 2:		SUITE 200
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91107
		BUSINESS PHONE:		626-305-5900

	MAIL ADDRESS:	
		STREET 1:		465 N. HALSTEAD ST.
		STREET 2:		SUITE 200
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91107
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xncr-20251105.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b609b15b-2be4-4cc8-8a6c-1f7b434b7558,g:de3b9ec1-07ad-496c-b23e-f24b21ef5b1d,d:89b90ad34b884fbd8d340b7e69eadc19-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xncr-20251105</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001326732</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xncr-20251105.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326732</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-05</xbrli:startDate><xbrli:endDate>2025-11-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i89b90ad34b884fbd8d340b7e69eadc19_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">of The Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November&#160;5, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">XENCOR,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:32.283%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.283%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36182</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-1622502</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(Commission </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(IRS Employer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Identification Number)</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">465 North Halstead Street, Suite 200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Pasadena</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">91107</ix:nonNumeric></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">(626)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">305-5900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see&#160;General Instruction A.2. below):</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">XNCR</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i89b90ad34b884fbd8d340b7e69eadc19_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;5, 2025, Xencor, Inc. (the &#8220;Company&#8221;) announced its financial results for the third quarter ended September&#160;30, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in &#8220;Item 2.02. Results of Operations and Financial Condition&#8221; of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i89b90ad34b884fbd8d340b7e69eadc19_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.28pt">Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="xncr-20251105xexx991.htm">Press Release issued by Xencor, Inc. on November 5, 2025.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i89b90ad34b884fbd8d340b7e69eadc19_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;5, 2025</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">XENCOR,&#160;INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Celia Eckert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Celia Eckert</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General Counsel &amp; Corporate Secretary</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>xncr-20251105xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i58932c76a3744e97915e92b73823d4ab_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:8pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div id="i58932c76a3744e97915e92b73823d4ab_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Xencor Reports Third Quarter 2025 Financial Results</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">PASADENA, Calif.--Nov. 5, 2025-- Xencor, Inc. (NASDAQ&#58;XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8220;Xencor&#8217;s two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and XmAb541, have demonstrated compelling clinical data in advanced clear cell renal cell carcinoma and advanced gynecologic and germ cell tumors, respectively. As we continue to advance through dose escalation and cohort expansions in Phase 1 studies evaluating these programs, we expect to identify recommended Phase 3 doses during 2026 to support initiation of pivotal studies during 2027,&#8221; said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. &#8220;The accelerating tempo of clinical development extends to our autoimmune portfolio. In the third quarter we dosed the first patient in our Phase 2b XENITH-UC study of XmAb942, our potential best-in-class antibody targeting TL1A for inflammatory bowel disease, to rapidly identify a pivotal dose regimen for those with moderately to severely active ulcerative colitis, and we dosed the first patient in our Phase 1b study of plamotamab in rheumatoid arthritis. We remain on-track to start clinical studies of XmAb657, our B-cell depleting TCE for the treatment of patients with autoimmune disease by year end 2025, and our lead TL1A x IL23p19 bispecific antibody, now designated XmAb412, in 2026.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;text-decoration:underline">Clinical Program Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Oncology</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;padding-left:14.5pt">XmAb819 (ENPP3 x CD3), a novel, first-in-class, tumor-targeted T-cell engaging XmAb&#174; 2+1 bispecific antibody in development for patients with advanced clear cell renal cell carcinoma (ccRCC).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%"> The first dose-expansion cohort in the ongoing Phase 1 study is enrolling patients as dose-escalation continues. Xencor plans to select a recommended Phase 3 dose during 2026 to support initiation of a pivotal study in advanced ccRCC during 2027.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">At the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in October 2025, Xencor presented initial results from the ongoing Phase 1 dose-escalation study of XmAb819. As of the data cut-off, 69 patients had received XmAb819 across 15 dose cohorts&#59; patients were heavily pre-treated, having received a median of 4 prior lines of therapy. All patients received prior anti-PD1 therapy and prior VEGF-TKI therapy, and 36% of patients were previously treated with a HIF2&#945; inhibitor. XmAb819 demonstrated evidence of anti-tumor activity and an acceptable safety profile that was generally well tolerated across dose levels. Of the 20 efficacy-evaluable patients treated at the dose levels that were preclinically predicted to be within the target dose range, 25% achieved a partial response (PR, per RECIST v1.1) as best response with a 70% disease control rate. The most common treatment-emergent adverse events (AEs) were cytokine release syndrome, rash and gastrointestinal-related toxicities that were primarily Grade 1 or 2 in severity and predominantly associated with prime-step dosing in the first four </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">weeks of treatment. No cases of treatment-related immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. No Grade 5 events were reported. Four patients (6%) were dose-reduced due to treatment-related AEs, and three patients (4%) discontinued treatment due to treatment-related AEs.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;padding-left:14.5pt">XmAb541 (CLDN6 x CD3), a novel, first-in-class, tumor-targeted T-cell engaging XmAb 2+1 bispecific antibody in development for patients with advanced gynecologic and germ cell tumors. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Xencor plans to select a recommended Phase 3 dose during 2026 to support initiation of a pivotal study during 2027. </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">In October 2025, Xencor presented early efficacy data from a cohort in the ongoing Phase 1 dose-escalation study of XmAb541, ahead of previously guided timelines to begin characterizing target dose range cohorts by year-end 2025. As of the data cut-off, nine patients received XmAb541 in the most recently completed escalation cohort. Confirmed partial responses per RECIST v1.1 were observed in three patients&#58; one patient with ovarian cancer and two patients with germ cell tumors. </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Autoimmune &#38; Inflammatory Diseases</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;padding-left:14.5pt">Plamotamab (CD20 x CD3), a clinical-stage, B-cell depleting bispecific T-cell engager in development for patients with rheumatoid arthritis (RA).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%"> Xencor is evaluating plamotamab in a Phase 1b proof-of-concept study, for patients with RA who have progressed through prior standard-of-care treatment. The first patient has been dosed in the study, and enrollment is ongoing.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;padding-left:14.5pt">XmAb942 (Xtend&#8482; anti-TL1A), a potential best-in-class, high-potency, extended half-life antibody in development for patients with inflammatory bowel disease.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%"> Xencor is conducting the global XENITH-UC Study, a Phase 2b study of XmAb942 in ulcerative colitis (UC). XENITH-UC is a randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe UC, whose disease has progressed after at least one conventional or advanced therapy. Patient enrollment in the study is ongoing.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;text-decoration:underline">Recent Partnership Developments</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;padding-left:14.5pt">Amgen&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Amgen initiated the Phase 3 XALience study of xaluritamig, a STEAP1 x CD3 XmAb 2+1 bispecific T-cell engager, in combination with abiraterone versus investigator&#8217;s choice therapy in patients with chemotherapy-na&#239;ve metastatic castration-resistant prostate cancer. XALute, a Phase 3 monotherapy study of xaluritamig in patients who have previously been treated with taxane-based chemotherapy, is enrolling. Amgen is exploring xaluritamig in other combinations and in earlier stages of prostate cancer with multiple Phase 1b studies ongoing. Xencor is eligible to receive $225 million in future milestone payments and tiered royalties on net sales that range from mid- to high-single digit percentages.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;padding-left:14.5pt">Astellas&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">In October 2025, the first clinical data from Astellas&#8217; investigational Claudin18.2-targeted, XmAb 2+1 bispecific CD3 T-cell engager, ASP2138, both as a monotherapy and in combination with standard of care therapies, were presented during the European Society for Medical Oncology congress in Berlin. Astellas is advancing ASP2138 for the treatment of patients with gastric, gastroesophageal junction and pancreatic cancers, and Astellas has announced that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">planning is ongoing to potentially initiate registrational studies. ASP2138 utilizes the XmAb 2+1 multivalent format to enable activation of T cells against Claudin-18.2 expressing tumor cells. Xencor is eligible to receive $232.5 million in future milestone payments and tiered royalties on net sales that range from high-single to low-double digit percentages.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;padding-left:14.5pt">Zenas Biopharma&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">In October 2025, Zenas announced positive results from the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis, in which the primary endpoint of the study was met. Zenas announced it expects to report topline results for the pivotal study of obexelimab in IgG4-Related Disease around year-end with additional readouts through mid-2026. Obexelimab targets CD19 with its variable domain and uses an XmAb Immune Inhibitor Fc Domain. In November 2021, Xencor licensed obexelimab to Zenas. Xencor is eligible to receive $460 million in future milestone payments and tiered royalties on net sales that range from mid-single-digit to mid-teen percentages, dependent on geography. As of September 30, 2025, Xencor owns 3,098,380 shares of common stock in Zenas.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Financial Guidance&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%"> Based on current operating plans, Xencor expects to end 2025 with between $570 million and $590 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2028.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%;text-decoration:underline">Financial Results for the Third Quarter Ended September 30, 2025</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Cash, cash equivalents and marketable debt securities totaled $633.9 million as of September 30, 2025, compared to $706.7 million as of December 31, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Revenue for the third quarter ended September 30, 2025 was $21.0 million, compared to $17.8 million for the same period in 2024. Revenue earned in the third quarters of 2025 and 2024 was primarily non-cash royalty revenue from Alexion and Incyte.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Research and development (R&#38;D) expenses for the third quarter ended September 30, 2025 were $54.4 million, compared to $58.2 million for the same period in 2024. Decreased R&#38;D spending for the third quarter of 2025 compared to 2024 reflects lower stock-based compensation and lower costs related to programs that are winding down or have been terminated.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">General and administrative (G&#38;A) expenses for the third quarter ended September 30, 2025 were $14.2 million, compared to $14.8 million for the same period in 2024. G&#38;A spending for the third quarter of 2025 remained relatively consistent compared to the same period in 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Other income, net, for the third quarter ended September 30, 2025 was $41.5 million, compared to $7.8 million for the same period in 2024. The increase for the third quarter of 2025, compared to 2024, is primarily driven by unrealized gains from marketable equity securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Net loss attributable to Xencor for the third quarter ended September 30, 2025 was $6.0 million, or $(0.08) on a fully diluted per share basis, compared to net loss of $46.3 million, or $(0.72) on a fully diluted per share basis, for the same period in 2024.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">About Xencor</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb&#174; technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein&#8217;s structure that result in new mechanisms of therapeutic action. For more information, please visit </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">www.xencor.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Certain statements contained in this press release may constitute forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as &#8220;potential,&#8221; &#8220;can,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;look forward,&#8221; &#8220;believe,&#8221; &#8220;committed,&#8221; &#8220;investigational,&#8221; &#8220;indicates,&#8221; &#8220;supports,&#8221; and similar terms, or by express or implied discussions relating to Xencor&#8217;s business, including, but not limited to, statements regarding expectations for clinical progress, planned presentations of clinical data, new XmAb candidates and programs, planned and in process clinical trials, financial guidance, the quotations from Xencor's president and chief executive officer, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics, the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, the risk of loss of key members of management, the risk that the fair value of our marketable equity securities will decline and the risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in Xencor's annual report on Form 10-K for the year ended December 31, 2024 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Xencor undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Contact</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Charles Liles </font></div><div><font style="color:#467886;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">cliles&#64;xencor.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">(626) 737-8118</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">For media&#58; </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Cassidy McClain </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Inizio Evoke </font></div><div><font style="color:#467886;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">cassidy.mcclain&#64;inizioevoke.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">  </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:134%">(619) 694-6291</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i58932c76a3744e97915e92b73823d4ab_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Xencor, Inc.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selected Consolidated Balance Sheet Data</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable debt securities - current</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,784&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,846&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,657&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,755&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable debt securities - long term</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,833&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,212&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,511&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,811&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951,945&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,485&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,432&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities related to the sales of future royalties - long term</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,776&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,234&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,328&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,495&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,919&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625,316&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674,026&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,811&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">951,945&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i58932c76a3744e97915e92b73823d4ab_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Xencor, Inc.</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborations, milestones, and royalties</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,999&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,796&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,339&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,700&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,367&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,226&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,610&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,630&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,151&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,767&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,603&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,300&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,518&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,993&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,213&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,930&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,519)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,197)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,874)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,230)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,492&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,755&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,507&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,110)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax expense and noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,027)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,442)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,367)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,340)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss including noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,027)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,442)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,484)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,340)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,275)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Xencor, Inc.</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,027)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,288)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,270)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,065)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Xencor, Inc. (basic and diluted)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.00)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating net loss per share (basic and diluted)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,413</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,122</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,310</font></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on marketable debt securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,127)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,990)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,663)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189,830)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; comprehensive loss attributable to the noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,154)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,275)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Xencor, Inc.</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,127)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,836)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,449)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,555)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xncr-20251105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b609b15b-2be4-4cc8-8a6c-1f7b434b7558,g:de3b9ec1-07ad-496c-b23e-f24b21ef5b1d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xncr="http://www.xencor.com/20251105" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.xencor.com/20251105">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xncr-20251105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xncr-20251105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.xencor.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xncr-20251105_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b609b15b-2be4-4cc8-8a6c-1f7b434b7558,g:de3b9ec1-07ad-496c-b23e-f24b21ef5b1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4cd72495-a4d0-462a-814a-82f43c630248_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_49d41012-2448-4e5c-b251-ef766f0b7fb7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5cb1e0a1-df3a-4455-bf0a-ccb29470eecc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bb23ff29-f285-44b5-ac0a-0bf257806a6e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3ba8f2d4-987e-47cd-ab47-3fe949ee6f86_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9d22121c-f15d-408e-98d9-7995e769e3ea_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b04dc374-797e-4471-a65c-e84f35b02541_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0cb3a1da-5ef7-413e-a70c-09dc33990f0a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_05f053e3-9377-4a5f-b34a-7c8e34748094_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4914d5be-fe85-4b69-aee9-e6aafbe4d466_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c2268e4c-3332-4825-b4d3-52fb38bdc4a5_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d4d42119-7c7b-4d01-a1c6-52b9274d7654_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_540e41be-0cd8-433b-a179-60781bdec56f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c0e2c94a-74df-4816-bcbd-df43cdbdad64_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4d59f79d-2856-4f56-b397-0d8389de523f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fbfe3163-4ac3-47d6-acef-007796c0b2d7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3a7b8c78-16dc-4479-936c-34acc74618b9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f07b4bd6-49ca-42bb-baf8-1ca1817708b4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4c1adfe7-e3a0-4097-8a88-2b257894c0a8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a6ac60a5-f28b-44cd-9843-9bd6aa7d7dbd_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_979b2108-b7ff-45e4-8791-e39e4f21a2fb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4ea7300f-eebf-4a78-b12a-dd12bc784dda_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xncr-20251105_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b609b15b-2be4-4cc8-8a6c-1f7b434b7558,g:de3b9ec1-07ad-496c-b23e-f24b21ef5b1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xencor.com/role/Cover" xlink:type="simple" xlink:href="xncr-20251105.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.xencor.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2d1fbb2b-b7d1-4dd5-a3e1-c9f546d6dd45" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_DocumentType_2d1fbb2b-b7d1-4dd5-a3e1-c9f546d6dd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1afaf5b3-1efc-4cec-ba9a-58d39b452bf6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_DocumentPeriodEndDate_1afaf5b3-1efc-4cec-ba9a-58d39b452bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_461620a9-384f-4a28-ae4d-0abb0f38d98f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityRegistrantName_461620a9-384f-4a28-ae4d-0abb0f38d98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2299796c-4fc0-4120-8323-40f83f8df9f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2299796c-4fc0-4120-8323-40f83f8df9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e2e1dcdd-18a4-4371-a1f6-fd20aed37929" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityFileNumber_e2e1dcdd-18a4-4371-a1f6-fd20aed37929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c5044e4f-bfc3-4d1b-8f98-72c1fcef26fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityTaxIdentificationNumber_c5044e4f-bfc3-4d1b-8f98-72c1fcef26fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ad65ac5d-b493-4e17-9f6f-7a5862c4457f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityAddressAddressLine1_ad65ac5d-b493-4e17-9f6f-7a5862c4457f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5dd95974-dfa0-43fc-8f53-dbe5eeb232bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityAddressCityOrTown_5dd95974-dfa0-43fc-8f53-dbe5eeb232bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bfe78b26-9b55-4b56-ad5b-89ed248faeb2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityAddressStateOrProvince_bfe78b26-9b55-4b56-ad5b-89ed248faeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1058959c-51ff-4c2f-8bab-83b74a5e145c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityAddressPostalZipCode_1058959c-51ff-4c2f-8bab-83b74a5e145c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7733f322-b694-46fb-a4b4-3b1bd5a2c6cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_CityAreaCode_7733f322-b694-46fb-a4b4-3b1bd5a2c6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a8f9f9d0-14d7-4bf7-9bf7-6c3a477cef54" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_LocalPhoneNumber_a8f9f9d0-14d7-4bf7-9bf7-6c3a477cef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ce130f9d-f476-4ab1-8a63-218b154d6165" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_WrittenCommunications_ce130f9d-f476-4ab1-8a63-218b154d6165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5a6c108b-e7e8-4e0b-9881-5ed00fb2e952" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_SolicitingMaterial_5a6c108b-e7e8-4e0b-9881-5ed00fb2e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_27eaac98-b4eb-4c5f-9677-439cabe89ae2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_PreCommencementTenderOffer_27eaac98-b4eb-4c5f-9677-439cabe89ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_999911df-3c60-4741-85c1-41dd89a32d37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_999911df-3c60-4741-85c1-41dd89a32d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0a2391ed-88a5-4a15-b861-e26967b60288" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_Security12bTitle_0a2391ed-88a5-4a15-b861-e26967b60288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_380105f8-6ca0-42ac-a29c-5977e0196d88" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_TradingSymbol_380105f8-6ca0-42ac-a29c-5977e0196d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1cc03b57-6997-43ff-8cc9-12f84ea85f40" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_SecurityExchangeName_1cc03b57-6997-43ff-8cc9-12f84ea85f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_287efcc3-94fd-43af-9e1f-f4997c494429" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityEmergingGrowthCompany_287efcc3-94fd-43af-9e1f-f4997c494429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3a6521c7-1194-4462-9bc0-251c64e08c79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_AmendmentFlag_3a6521c7-1194-4462-9bc0-251c64e08c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9985ae3f-c999-4ac3-93dd-27e76096c7df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8a609b8-8f99-4682-80e9-44a5666853df" xlink:to="loc_dei_EntityCentralIndexKey_9985ae3f-c999-4ac3-93dd-27e76096c7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M! ?B(7J3<D,?G30X^)') \$!\+L/3QX,CDEZ_JLL0\%#D/X_-RU?OCN]/8%
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M#OH+Z2T*! *!0""H%Y(#WM%)/WB#5<'7HU)!?G,R""YONOKJ]]-;% @$ H%
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MH=!%9CAWLR(N59"A'\+9\S3($4GD\Q<E/'\CJW*O=Z4\_R>3:LR<R!G[),B
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MUJVG"O^M.>>GR:F'2[/LR?#3YN$K! *!0" 0[-@T-?T_[JQQ]V:<ID
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XENCOR,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1622502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">465 North Halstead Street, Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">305-5900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XNCR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xncr-20251105.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xencor.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="xncr-20251105.htm">xncr-20251105.htm</File>
    <File>xncr-20251105.xsd</File>
    <File>xncr-20251105_lab.xml</File>
    <File>xncr-20251105_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "xncr-20251105.htm": {
   "nsprefix": "xncr",
   "nsuri": "http://www.xencor.com/20251105",
   "dts": {
    "inline": {
     "local": [
      "xncr-20251105.htm"
     ]
    },
    "schema": {
     "local": [
      "xncr-20251105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "xncr-20251105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xncr-20251105_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.xencor.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xncr-20251105.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xncr-20251105.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.xencor.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001326732-25-000086-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001326732-25-000086-xbrl.zip
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M?4QE]B!K*:_/6DKZ(_GJR_JM_P-02P,$%     @ 18!E6V.@CF)= @  \P8
M !$   !X;F-R+3(P,C4Q,3 U+GAS9,U4R6[;,!"]^RM8G4MMEN,%L0,T08 "
M[H(T07,K2&ID$Y%(E:1BY^]+TB(<)W$*]U2=J)GW9GF<X?G%MJG1(RC-I9A'
M69Q&" 23)1>K>71W>XTGT<5B,#C_@/']IYLENI*L:T 8=*F &"C1AILU,FM
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MQ^RM#::J@.\7_&INA-$ABD-(N+0_J(HAE]K (*"4Q3(06 T^R-&*?&2L'K5
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M^$:<CI&O85*92 45B,18WH0)H">;?_I2QR!:F\<LYM)EOP(UI<?.^$A.>&+
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MI:RX!.<&FXO!L37NI4]M<QK+SUN9=:F"70 R4.)Y-T6,!6FD<L!4J[H14"G
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MP3;]G')\X7'"!_5-<1DQW(Y!9@QWP=Z5G&!HI@!BAVJ_&8^N*0VNB)U(]O'
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M=P+_&R6^]_[_ 5!+ 0(4 Q0    ( $6 95O =NV%U@X  &AB   1
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M4$L! A0#%     @ 18!E6WJ05=6A'P  M54! !@              ( !I2(
M 'AN8W(M,C R-3$Q,#5X97AX.3DQ+FAT;5!+!08     !0 % $H!  !\0@
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>xncr-20251105_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xncr-20251105.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326732</identifier>
        </entity>
        <period>
            <startDate>2025-11-05</startDate>
            <endDate>2025-11-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001326732</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">XENCOR,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36182</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-1622502</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">465 North Halstead Street, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">91107</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">(626)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">305-5900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">XNCR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
